Close Menu

NEW YORK (GenomeWeb) – ArcherDx announced today that it has raised $60 million in a Series B financing round.

ArcherDx said it will use the proceeds from the funding round to scale operations and advance its companion diagnostic program, which includes solid tumors, hematological malignancies, and circulating tumor DNA applications. The firm will also use the funding to further expand its minimal residual disease (MRD) monitoring program.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.